VIYASH

Viyash Scientific Limited

Integrated pharmaceutical platform for animal and human health

Healthcare›Healthcare›Pharmaceuticals & Biotechnology›Pharmaceuticals

viyash.com(opens the company website in a new tab)
Ask AI

Key metrics

Price as of 2026-10-16

Stock price
₹226.00
Market cap
9,859 Cr
Stock P/E
57.6
P/B
3.39
Dividend yield
0.0%
ROE (FY26)
5.7%
ROCE (FY26)
11.8%
Operating margin (FY26)
12.2%
Debt / equity (FY26)
0.15
OCF / EBITDA (FY26)
49.5%
OCF / EBITDA (3Y)
49.9%

Full years shown; sign in free for the trailing twelve months. Learn about these metrics →

Price & valuation

Share price and valuation multiples (P/E, P/B and more) over time.

Loading price history…

Compare with peers

Loading peers…

What you need to know

Viyash Scientific makes pharmaceutical ingredients (APIs) and finished medicines for animal and human health, and does contract development and manufacturing for innovator companies.

Company snapshot

43rdBy market cap

Ranked among 119 companies in Pharmaceuticals.

What we see

Positives
  • ✓Debt-to-equity of 0.15x — the company is largely funded by its own money, not borrowed funds.
Concerns
  • ✗Only 50% of operating profit came in as cash over the last three years — much of it is tied up in unpaid bills or stock.

Statement tables · Consolidated

Switches quarterly, P&L, balance sheet, and cash flow. Key metrics and ratios stay on consolidated when available.

Amounts in ₹ Cr · tap + to expand rows

Quarterly results

Quarterly · ₹ Cr · tap + rows to expand

MetricSept 2023Dec 2023Mar 2024Jun 2024Sept 2024Dec 2024Mar 2025Jun 2025Sept 2025Dec 2025Mar 2026Jun 2026
Sales346 Cr329 Cr361 Cr390 Cr369 Cr391 Cr402 Cr441 Cr424 Cr858 Cr920 Cr946 Cr
Operating expenses (approx.)331 Cr307 Cr329 Cr348 Cr330 Cr356 Cr355 Cr389 Cr368 Cr683 Cr736 Cr768 Cr
EBITDA15 Cr22 Cr32 Cr42 Cr39 Cr35 Cr46 Cr52 Cr56 Cr176 Cr184 Cr178 Cr
OPM %4.4%6.8%8.9%10.8%10.6%8.8%11.5%11.8%13.1%20.5%20.0%18.8%
Other income2 Cr5 Cr4 Cr3 Cr5 Cr6 Cr2 Cr4 Cr2 Cr14 Cr16 Cr8 Cr
Interest13 Cr13 Cr12 Cr16 Cr14 Cr15 Cr15 Cr14 Cr14 Cr17 Cr15 Cr13 Cr
Depreciation15 Cr15 Cr16 Cr16 Cr17 Cr17 Cr16 Cr15 Cr15 Cr59 Cr60 Cr62 Cr
Profit before tax-3 Cr1 Cr3 Cr12 Cr8 Cr8 Cr16 Cr26 Cr27 Cr73 Cr125 Cr112 Cr
Tax %-122.4%-616.0%51.7%24.5%19.7%20.0%36.4%31.2%27.8%33.6%47.0%29.5%
Net profit-7 Cr11 Cr1 Cr9 Cr6 Cr6 Cr10 Cr18 Cr20 Cr49 Cr66 Cr79 Cr
EPS (₹)₹-0.34₹0.33₹-0.04₹0.26₹0.10₹0.14₹0.37₹0.57₹0.59₹0.89₹1.20₹1.51

Profit & loss (annual)

Annual · last column is TTM · ₹ Cr · tap + to expand

MetricMar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Sales689 Cr849 Cr1,039 Cr1,179 Cr1,362 Cr1,413 Cr1,421 Cr1,370 Cr1,551 Cr3,420 CrSign in free for the trailing twelve months
Operating expenses (approx.)646 Cr766 Cr914 Cr1,009 Cr1,150 Cr1,303 Cr1,409 Cr1,308 Cr1,390 Cr2,768 CrSign in free for the trailing twelve months
EBITDA43 Cr83 Cr125 Cr170 Cr212 Cr109 Cr12 Cr61 Cr162 Cr653 CrSign in free for the trailing twelve months
OPM %6.2%9.8%12.0%14.4%15.6%7.7%0.8%4.5%10.4%19.1%Sign in free for the trailing twelve months
Other income11 Cr17 Cr9 Cr10 Cr8 Cr11 Cr6 Cr11 Cr15 Cr44 CrSign in free for the trailing twelve months
Interest28 Cr33 Cr33 Cr36 Cr24 Cr16 Cr36 Cr48 Cr61 Cr69 CrSign in free for the trailing twelve months
Depreciation40 Cr41 Cr42 Cr51 Cr51 Cr51 Cr56 Cr62 Cr66 Cr234 CrSign in free for the trailing twelve months
Profit before tax-14 Cr444 Cr59 Cr94 Cr137 Cr53 Cr-138 Cr-55 Cr44 Cr349 CrSign in free for the trailing twelve months
Tax %3.7%3.0%3.4%12.8%23.6%15.6%11.4%45.8%27.2%35.6%Sign in free for the trailing twelve months
Net profit-16 Cr431 Cr57 Cr82 Cr104 Cr45 Cr-122 Cr-30 Cr32 Cr225 CrSign in free for the trailing twelve months
EPS (₹)₹-0.57₹17.40₹2.00₹2.87₹3.87₹1.67₹-4.88₹-1.44₹0.88₹4.09Sign in free for the trailing twelve months
Dividend payout %————0.0%27.4%——5.7%2.2%Sign in free for the trailing twelve months
Sign in free for the trailing twelve months

The latest four quarters added up, next to each full year

Balance sheet

Annual · ₹ Cr · tap + rows to expand

MetricMar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity capital49 Cr49 Cr49 Cr50 Cr50 Cr50 Cr50 Cr50 Cr50 Cr87 Cr
Reserves928 Cr599 Cr657 Cr693 Cr678 Cr643 Cr649 Cr607 Cr654 Cr2,824 Cr
Borrowings360 Cr256 Cr267 Cr284 Cr197 Cr315 Cr398 Cr451 Cr446 Cr436 Cr
Other liabilities551 Cr402 Cr374 Cr446 Cr420 Cr386 Cr382 Cr376 Cr385 Cr1,078 Cr
Total liabilities1,905 Cr1,343 Cr1,388 Cr1,518 Cr1,393 Cr1,441 Cr1,529 Cr1,540 Cr1,602 Cr4,628 Cr
Fixed assets (net)400 Cr214 Cr227 Cr345 Cr319 Cr317 Cr301 Cr249 Cr232 Cr1,138 Cr
CWIP2 Cr13 Cr17 Cr11 Cr29 Cr9 Cr51 Cr11 Cr15 Cr69 Cr
Investments428 Cr239 Cr180 Cr171 Cr83 Cr38 Cr0.05 Cr4 Cr0.08 Cr0.07 Cr
Loans & advances——0.76 Cr0.35 Cr0.19 Cr0.25 Cr0.34 Cr0.14 Cr0.21 Cr0.12 Cr
Inventories161 Cr159 Cr200 Cr219 Cr264 Cr348 Cr346 Cr346 Cr385 Cr803 Cr
Trade receivables255 Cr258 Cr278 Cr319 Cr346 Cr329 Cr341 Cr336 Cr363 Cr1,045 Cr
Cash & bank44 Cr40 Cr68 Cr68 Cr54 Cr57 Cr42 Cr65 Cr63 Cr256 Cr
Other assets616 Cr420 Cr417 Cr384 Cr298 Cr343 Cr448 Cr530 Cr544 Cr1,317 Cr
Total assets1,905 Cr1,343 Cr1,388 Cr1,518 Cr1,393 Cr1,441 Cr1,529 Cr1,540 Cr1,602 Cr4,628 Cr

Cash flows

Annual · ₹ Cr · tap + rows to expand · last column includes FCF

MetricMar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Cash from operating activity-7 Cr45 Cr116 Cr115 Cr115 Cr31 Cr17 Cr31 Cr83 Cr323 Cr
Cash from investing-116 Cr7 Cr-68 Cr-72 Cr10 Cr-94 Cr-65 Cr-6 Cr-25 Cr-84 Cr
Cash from financing147 Cr-57 Cr-20 Cr-43 Cr-139 Cr67 Cr32 Cr-1 Cr-61 Cr-123 Cr
Net cash flow24 Cr-5 Cr28 Cr0.31 Cr-14 Cr4 Cr-16 Cr23 Cr-2 Cr115 Cr
Free cash flow (OCF − Capex)-86 Cr-2 Cr91 Cr75 Cr62 Cr-2 Cr-69 Cr-0.21 Cr44 Cr188 Cr

Ratios

MetricMar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
ROCE %1.0%50.8%9.0%12.1%16.5%6.6%-8.9%-0.6%8.6%11.8%
ROE %-1.4%62.9%6.5%8.9%12.3%5.6%-16.2%-5.0%2.8%5.7%
Debtor days13511197999385878985111
Inventory days240168160157163189182206227212
Days payable302170168158142140128155151158
Cash conversion cycle721099098114134141141161166
OCF / EBITDA %-16.7%54.5%92.9%67.7%54.1%28.0%n.m.49.8%51.5%49.5%
OCF / EBITDA % (3 years)——61.4%73.1%68.2%53.0%48.6%42.7%55.6%49.9%
Debt / equity0.370.400.380.380.270.450.570.690.630.15
Current ratio1.331.251.381.501.551.541.481.291.732.38
Net debt / EBITDA7.37—1.591.270.672.3529.816.292.370.28